Skip to main content

Table 2 Anti-diabetic drugs taken before randomisation

From: A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk

Parameters

N

N

213

M/F

106/107

Lifestyle

5 (2.34) 2/3)

Sulfonylureas, n (%) (M/F)

42 (19.7) (18/24)

 Glyburide

3 (7.1) (1/2)

 Glimepiride

17 (40.5) (10/7)

 Gliclazide

22 (52.4) (12/10)

Biguanides, n (%) (M/F)

153 (71.8) (71/82)

 Metformin

153 (100) (71/82)

Glinides, n (%) (M/F)

32 (15.0) (17/15)

 Repaglinide

32 (100) (17/15)

α-glucosidase inhibitors, n (%) (M/F)

33 (15.5) (14/19)

 Acarbose

33 (100) (14/19)

Thiazolidinediones, n (%) (M/F)

28 (13.1) (15/13)

 Pioglitazone

24 (85.7) (12/12)

 Rosiglitazone

4 (14.3) (3/1)

DPP-4 inhibitors, n (%) (M/F)

33 (15.5) (17/16)

 Sitagliptin

12 (36.4) (6/6)

 Vildagliptin

10 (30.3) (6/4)

 Saxagliptin

7 (21.2) (3/4)

 Linagliptin

4 (12.1) (2/2)

GLP-1 analogs, n (%) (M/F)

15 (7.0) (8/7)

 Exenatide

10 (66.7) (7/3)

 Liraglutide

5 (33.3) (2/3)

  1. M males, F females, DPP-4 dipeptidyl peptidase-4, GLP-1 glucagon-like peptide-1.